Rhythm Pharmaceuticals (RYTM) Capital Expenditures (2017 - 2023)

Rhythm Pharmaceuticals (RYTM) has 7 years of Capital Expenditures data on file, last reported at -$1000.0 in Q4 2023.

• Capital Expenditures for Q4 2023 came in at -$1000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2023 was $47000.0 (down 83.27% YoY), and the FY2025 annual result was $953000.0, changed N/A from the prior year.
• Capital Expenditures declined to -$1000.0 in Q4 2023 per RYTM's latest filing, from $1000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.3 million in Q2 2019 and troughed at -$1000.0 in Q4 2022.
• A 5-year average of $282066.7 and a median of $84000.0 in 2020 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 958.33% in 2022 and fell as far as 101.47% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $259000.0 in 2019, then slumped by 67.57% to $84000.0 in 2020, then decreased by 19.05% to $68000.0 in 2021, then sank by 101.47% to -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023.
• Business Quant data shows RYTM's Capital Expenditures at -$1000.0 in Q4 2023, $1000.0 in Q3 2023, and $47000.0 in Q1 2023.